Irish CRO Icon rolls out digital platform developed with Dimension Data

HPE has acquired AI and big data company BlueData for an undisclosed sum (Image PeopleImages / iStockPhoto)
Dublin-based CRO Icon had adopted a new digital platform developed with Dimension Data designed to enhance efficiency and productivity of its clients’ drug and medical device pipelines. (PeopleImages/iStockPhoto)

Dublin-based CRO Icon had adopted a new digital platform developed with Dimension Data designed to enhance efficiency and productivity of its clients’ drug and medical device pipelines.

The platform has been launched throughout the CRO to help support digital trials and patient interaction so that medical professionals can reach those who need it, a Dimension Data spokesperson said in an e-mail.

The platform was designed to aid in reducing complexity and cost for drug and device companies in bring new products to market.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

Last year, Icon launched a new, paperless solution for managing the clinical investigator financial disclosure forms mandated by the FDA. Known as Firecrest Financial Disclosure software, it allows sponsors to electronically gather, distribute, track and manage completion of the forms required under the regulatory agency’s rules. The Irish company hopes the system will lower the risks of regulatory noncompliance and reduce administrative costs versus traditional distribution and tracking.

Read more on

Suggested Articles

Clinical trial firm Phesi’s new report is some grim reading for the life science industry: Studies for new drugs are still suffering.

Tempus fugit: And time especially flies when it comes clinical trials. Covance is teaming up with the suitably named Tempus to clip its wings.

PPD has raised its quarterly guidance after weathering the COVID-19 storm and is immediately making a secondary offering of 38 million shares.